The Korean-developed COVID-19 vaccine GBP510, is administered to phase 3 clinical trial subjects f...

- Phase I/II stage 1 confirms 5~8 folds of neutralizing antibody titer compared to human convalesce...

- GBP510, a COVID-19 vaccine candidate was submitted an IND for a Phase III clinical study in Korea ...

ESG Committee will review major management strategies related to the environment, society, and gove...

- SK bioscience invested about 150 billion KRW in the expansion of existing vaccine manufacturing p...

SK bioscience’s COVID-19 vaccine candidate, ‘GBP510’ secures up to 173.4 million USD of additional ...

SK bioscience’s Novavax’ COVID-19 vaccine candidate facility obtained GMP certification from the EMA...

IPO listing ceremony held at the Korea Exchange on the 18th- “Another leap forward as a global compa...

- CEPI grants up to 14.2 million USD of funding to support development of a vaccine against COVID-1...

- SK bioscience obtained exclusive rights to manufacture, marketing, and distribute the NVX-CoV237...